DelveInsight has launched a new report on “Congestive Heart Failure Market Insights, Epidemiology, and Market Forecast-2032”.
DelveInsight’s “Congestive Heart Failure Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Congestive Heart Failure, historical and forecasted epidemiology as well as the Congestive Heart Failure market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the Congestive Heart Failure Market Report:
- The total prevalent cases of Heart Failure in 2021 in the 7MM were estimated to be 16,630,560. The highest prevalent cases of this disease were seen in the United States were 6,543,570
- In the United States, approximately 550,000 new cases are diagnosed each year
- According to the research, around 1.4 million people who suffer from Congestive Heart Failure are under the age of 60
- The prevalence of Congestive Heart Failure is suffered by both the genders
- In the year 2021, the estimated cases of Congestive Heart Failure were 2,512,731 in males and 2,722,125 in females in the US
Request for the Sample Report: https://www.delveinsight.com/sample-request/congestive-heart-failure-market
Key benefits of the report:
- Congestive Heart Failure market report covers a descriptive overview and comprehensive insight of the Congestive Heart Failure Epidemiology and Congestive Heart Failure market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- The Congestive Heart Failure market report provides insights on the current and emerging therapies.
- Congestive Heart Failure market report provides a global historical and forecasted market covering drug outreach in 7MM.
- The Congestive Heart Failure market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Congestive Heart Failure market.
Got queries? Click here to know more about the Congestive Heart Failure Market Landscape
Congestive Heart Failure Overview:
Heart Failure (HF) is also known as congestive HF. It is also bifurcated as left-side HF (when the heart is unable to pump enough oxygen in the blood to the body) and right-side HF (when the heart is unable to fill itself with enough blood). Another term for HF is cor pulmonale which means that right-side HF is caused by high blood pressure in the pulmonary arteries and right ventricle. Some people face the problem of HF when the heart has trouble pumping enough blood to support other organs in the body. Some people have a hardening and stiffening of the heart muscle themself, which blocks or reduces blood flow towards the heart. HF initially causes shortness of breath and fatigue (tiredness) and the right side may further cause fluid to build up in the feet, ankles, legs, liver, abdomen, and the veins in the neck.
HF is triggered by structural and functional limitations in the myocardium resulting in damage to ventricular filling or the ejection of blood by the heart. The most common cause of HF is lowering of the left ventricular myocardial utility along with the dysfunction of pericardium, myocardium, endocardium, heart valves, or large vessels alone or in the combination.
Congestive Heart Failure Symptoms:
The symptoms of Congestive Heart Failure include-
- Shortness in Breathing while doing any activity or laying down
- Body Fatigue and weakness
- Swelling in the legs ankles and feet
- Irregular Heartbeats
- Swelling in the Belly area
Congestive Heart Failure Market
The dynamics of the Congestive Heart Failure market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as OPC-61815 (Otsuka Pharmaceutical), Omecamtiv Mecarbil (Cytokinetics), Rexlemestrocel-L (Mesoblast) and others during the forecasted period 2019-2032.
Learn more by requesting for sample @Congestive Heart Failure Market Landscape
Congestive Heart Failure Pipeline Therapies:
- Entresto
- Jardiance
- Verquvo
- Farxiga
- Corlanor
- Lixivaptan
- Irbesartan
- KW-3902IV
Congestive Heart Failure Pipeline Key Companies:
- Novartis
- Boehringer Ingelheim and Eli Lilly
- Bayer and Merck
- AstraZeneca
- Amgen
- Otsuka Pharmaceutical
- Cytokinetics
- Mesoblast
- Novo Nordisk
- Lexicon Pharmaceuticals
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Congestive Heart Failure Patient Share (%) Overview at a Glance
5. Congestive Heart Failure Market Overview at a Glance
6. Congestive Heart Failure Disease Background and Overview
7. Congestive Heart Failure Epidemiology and Patient Population
8. Country-Specific Patient Population of Congestive Heart Failure
9. Congestive Heart Failure Current Treatment and Medical Practices
10. Unmet Needs
11. Congestive Heart Failure Emerging Therapies
12. Congestive Heart Failure Market Outlook
13. Country-Wise Congestive Heart Failure Market Analysis (2018–2030)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Congestive Heart Failure Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Click here to read more about Congestive Heart Failure Market Outlook 2032
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com